Telisotuzumab adizutecan

Generic Name: Telisotuzumab adizutecan

Clinical Trials

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Telisotuzumab Adizutecan
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Panitumumab
Drug: Bevacizumab

First Posted Date: 2025-02-11

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 390

Registration Number: NCT06820463

Locations: 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 268007, Jerusalem, Israel
🇮🇱
Rabin Medical Center /ID# 268008, Petah Tikva, Israel
🇺🇸
Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States

and more 7 locations

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1

Recruiting

Conditions: Non Small Cell Lung Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Telisotuzumab Adizutecan
Drug: Budigalimab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2025-01-13

Last Posted Date: 2025-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 172

Registration Number: NCT06772623

Locations: 🇺🇸
Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
🇺🇸
Mid Florida Hematology And Oncology Center /ID# 273777, Orange City, Florida, United States

and more 17 locations

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: ABBV-400
Drug: Budigalimab
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2024-10-04

Last Posted Date: 2025-05-18

Lead Sponsor: AbbVie

Target Recruit Count: 180

Registration Number: NCT06628310

Locations: 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630, Irvine, California, United States
🇺🇸
UCLA - Santa Monica /ID# 270024, Santa Monica, California, United States

and more 9 locations

A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer

Phase 3

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: ABBV-400
Drug: Trifluridine/Tipiracil
Drug: Bevacizumab

First Posted Date: 2024-09-26

Last Posted Date: 2025-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 460

Registration Number: NCT06614192

Locations: 🇨🇳
Taipei Veterans General Hospital /ID# 267628, Taipei City, Taiwan
🇨🇳
Linkou Chang Gung Memorial Hospital /ID# 267637, Taoyuan City, Taiwan
🇺🇸
Winship Cancer Institute of Emory University /ID# 266884, Atlanta, Georgia, United States

and more 47 locations

Study to Assess Adverse Events and How Intravenously (IV) Infused ABBV-400 Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: ABBV-400

First Posted Date: 2024-06-18

Last Posted Date: 2024-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 27

Registration Number: NCT06464692

Locations: 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309, Guangzhou, Guangdong, China
🇨🇳
First Affiliated Hospital of China Medical University /ID# 263338, Shenyang, Liaoning, China
🇨🇳
Beijing Cancer Hospital /ID# 263297, Beijing, Beijing, China

and more 4 locations

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2

Recruiting

Conditions: Unresectable Metastatic Colorectal Cancer

Interventions: Drug: ABBV-400
Drug: Bevacizumab
Drug: Folinic Acid
Drug: Fluorouracil
Drug: Irinotecan

First Posted Date: 2023-10-30

Last Posted Date: 2025-03-25

Lead Sponsor: AbbVie

Target Recruit Count: 206

Registration Number: NCT06107413

Locations: 🇮🇱
Meir Medical Center /ID# 257089, Kfar Saba, HaMerkaz, Israel
🇺🇸
Mayo Clinic Arizona /ID# 262610, Phoenix, Arizona, United States
🇺🇸
Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States

and more 57 locations

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancers
Esophageal Squamous Cell Carcinoma
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Head and Neck Squamous-Cell Carcinoma
Platinum Resistant High Grade Epithelial Ovarian Cancer

Interventions: Drug: ABBV-400

First Posted Date: 2023-10-16

Last Posted Date: 2025-03-10

Lead Sponsor: AbbVie

Target Recruit Count: 260

Registration Number: NCT06084481

Locations: 🇺🇸
City of Hope National Medical Center /ID# 258645, Duarte, California, United States
🇺🇸
University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128, Aurora, Colorado, United States
🇺🇸
Florida Cancer Specialists /ID# 261569, Sarasota, Florida, United States

and more 51 locations

Expanded Access to Telisotuzumab Adizutecan

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2023-08-09

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Registration Number: NCT05982873

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Advanced Solid Tumors
Non-Small Cell Lung Cancer
Gastroesophageal Adenocarcinoma

Interventions: Drug: ABBV-400
Drug: Trifluridine/Tipiracil
Drug: Bevacizumab

First Posted Date: 2021-09-01

Last Posted Date: 2025-02-20

Lead Sponsor: AbbVie

Target Recruit Count: 520

Registration Number: NCT05029882

Locations: 🇫🇷
Centre Georges François Leclerc /ID# 244450, Dijon, France
🇫🇷
AP-HP - Hopital Européen Georges Pompidou /ID# 250481, Paris, France
🇮🇱
Rambam Health Care Campus /ID# 231218, Haifa, H_efa, Israel

and more 79 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy